Adjuvant Pembrolizumab/Chemotherapy Fails to Improve DFS High-Risk Endometrial Cancer
Adjuvant pembrolizumab plus chemotherapy did not improve DFS in high-risk endometrial cancer patients overall, but showed a clinically meaningful benefit in those with dMMR tumors. The 2-year DFS rates were 92% with pembrolizumab vs. 80% with placebo in the dMMR subgroup, while rates were 69% vs. 75% in the pMMR subgroup. Safety profiles were consistent with known checkpoint inhibitors, with no treatment-related deaths.
Reference News
Adjuvant pembrolizumab plus chemotherapy did not improve DFS in high-risk endometrial cancer patients overall, but showed a clinically meaningful benefit in those with dMMR tumors. The 2-year DFS rates were 92% with pembrolizumab vs. 80% with placebo in the dMMR subgroup, while rates were 69% vs. 75% in the pMMR subgroup. Safety profiles were consistent with known checkpoint inhibitors, with no treatment-related deaths.